EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictors of response to Radioactive Iodine Therapy in Intermediate and high risk patients with papillary thyroid carcinoma

Azam Keshavarzi, Fariba Alaei-Shahmiri, Babak Fallahi, Zahra Emami, Mojtaba Malek, Mohammad E Khamseh

BMC Endocrine Disorders · 2024

DOI: 10.1186/s12902-024-01648-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BMC Endocrine Disorders, 2024. Verfasst von Azam Keshavarzi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine Research Center, Institute of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Iran University of Medical…. Hauptthemen laut MEDLINE: Iodine Radioisotopes, Thyroid Neoplasms, Thyroidectomy, Thyroid Cancer, Papillary. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Radioactive iodine (RAI) therapy is the standard treatment approach after total thyroidectomy in patients with papillary thyroid carcinoma (PTC). We aimed to identify predictive factors of response to the treatment in intermediate and high-risk patients with PTC. In addition, the impact of multiple RAI treatments was explored.

Methods

In a 3-year retrospective study, data from intermediate and high-risk patients with PTC who received RAI therapy following total thyroidectomy, were analyzed by the end of year-one and year-three. Demographic data, tumor size, capsular/vascular invasion, extrathyroidal extension, local or distant metastasis, initial dose and cumulative dose of RAI, serum thyroglobulin(Tg), antithyroglobulin antibody(TgAb), and imaging findings were investigated. Patients with an excellent response to a single dose of RAI treatment, after three years of follow-up were classified as the “Responder group”. Excellent response was defined as stimulated serum Tg less than 1 ng/ml, or unstimulated serum Tg less than 0.2 ng/ml in TgAb-negative patients with negative imaging scans.

Results

333 patient records with a complete data set were analyzed in this study. After three years of initial treatment, 271 patients were non-responders (NR) and 62 were responders (R). At baseline, the median pre-ablation serum Tg level was 5.7 ng/ml in the NR group, and 1.25 ng/ml in the R group ( P < 0.001). TSH-Stimulated serum Tg greater than 15.7 ng/ml, was associated with response failure even after multiple RAI therapy, AUC: 0.717(0.660–0.774), sensitivity: 52.5%, specificity: 89.47%, P < 0.001. On the other hand, multiple RAI therapy was associated with excellent response in 16.2% of the patients. The chance of ER was decreased by 74% if initial post-operation ultrasound imaging confirmed the presence of locoregional involvement, OR 0.26, (95% CI: 0.12–0.55), P < 0.001.

Conclusion

Stimulated serum Tg and locoregional involvement after total thyroidectomy are predictive factors of non-response to RAI therapy in intermediate and high-risk patients with PTC. In addition, a minority of patients achieve excellent response after multiple RAI therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iodine RadioisotopesThyroid NeoplasmsThyroidectomyThyroid Cancer, PapillaryHumansMaleFemaleRetrospective StudiesMiddle AgedAdultFollow-Up StudiesPrognosisAgedThyroglobulinTreatment OutcomeYoung AdultRisk FactorsCarcinoma, Papillary

Stichwörter der Autor:innen

Papillary thyroid carcinomaRadioactive Iodine TherapyThyroglobulin, locoregional involvementTreatment response, predictive factor

Substanzen

Iodine RadioisotopesThyroglobulin

Autor:innen und Institutionen

  • Endocrine Research Center, Institute of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
  • Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, No. 10, Firoozeh St., Vali-asr Ave., Vali-asr Sq, Tehran, Iran.
  • Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Research Center for Prevention of Cardiovascular Disease, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran.
  • Endocrine Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, No. 10, Firoozeh St., Vali-asr Ave., Vali-asr Sq, Tehran, Iran. khamseh.m@iums.ac.ir.

Zitieren

APA

Keshavarzi, A., Alaei-Shahmiri, F., Fallahi, B., Emami, Z., Malek, M., & Khamseh, M. E. (2024). Predictors of response to Radioactive Iodine Therapy in Intermediate and high risk patients with papillary thyroid carcinoma. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-024-01648-8

Vancouver

Keshavarzi A, Alaei-Shahmiri F, Fallahi B, Emami Z, Malek M, Khamseh ME. Predictors of response to Radioactive Iodine Therapy in Intermediate and high risk patients with papillary thyroid carcinoma. BMC Endocrine Disorders. 2024. doi:10.1186/s12902-024-01648-8

BibTeX
@article{Keshavarzi2024,
  author = {Keshavarzi, Azam and Alaei-Shahmiri, Fariba and Fallahi, Babak and Emami, Zahra and Malek, Mojtaba and Khamseh, Mohammad E},
  title = {Predictors of response to Radioactive Iodine Therapy in Intermediate and high risk patients with papillary thyroid carcinoma},
  journal = {BMC Endocrine Disorders},
  year = {2024},
  doi = {10.1186/s12902-024-01648-8}
}
Kostenlos starten →